Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

10.9%

13 terminated/withdrawn out of 119 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

49%

58 trials in Phase 3/4

Results Transparency

32%

25 of 78 completed trials have results

Key Signals

10 recruiting25 with results6 terminated7 withdrawn

Enrollment Performance

Analytics

Phase 4

33(38.8%)

Phase 3

25(29.4%)

N/A

17(20.0%)

Phase 1

5(5.9%)

Phase 2

5(5.9%)

85Total

Phase 4(33)

Phase 3(25)

N/A(17)

Phase 1(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (119)

Showing 20 of 119 trials

NCT05042544Recruiting

The Australian HCV Point-of-Care Testing Program

Role: lead

NCT00931463Phase 4Completed

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

Role: lead

NCT07164430Completed

The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory

Role: collaborator

NCT05415267Phase 3Recruiting

Immunosuppression and COVID-19 Boosters

Role: lead

NCT07122219Not ApplicableRecruiting

Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons

Role: collaborator

NCT06317051Phase 3Active Not Recruiting

Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

Role: lead

NCT07145736Phase 4Recruiting

Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases